Clinical trials: MRD-positive
Acute Lymphoblastic Leukemia
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
This investigator-initiated, prospective, single-arm, open-label, single-center clinical study aims to evaluate the efficacy and safety of Inaticabtagene autoleucel (Inati-cel;CNCT19)CD19 CAR-T theraphy in adults B-ALL that are…
- Trial name
- NCT06718244
- Testing
- single dose of Inaticabtagene autoleucel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Acute Lymphoblastic Leukemia
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
A study on the effectiveness and safety of haploidentical hematopoietic stem cell transplantation in patients with MRD positive CD19+ ALL treated with conditioning regimens containing Blinatumomab
- Trial name
- NCT06125106
- Testing
- Blinatumomab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Zhejiang University
Minimal Residual Disease, Leukemia, Lymphoblastic, Acute
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
This study will test the ability of clofarabine + cytarabine to eliminate minimal residual disease (MRD) in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete…
- Conditions
- Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute
- Trial name
- NCT01158885
- Testing
- Clofarabine, Cytarabine intravenous, Methotrexate
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
ALL, Adult
Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy
T-ALL accounts for about 15%-25% of Ph-negative ALL, and its clinical prognosis is worse than B-ALL. The successful application of immunotherapy has brought revolutionary progress to the treatment of ALL.
- Trial name
- T-ALL-2024 (NCT06570915)
- Testing
- Daratumumab Injection
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Diffuse Large B-Cell Lymphoma
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
This is a prospective, multicenter, single-arm, open-label phase 2 study designed to evaluate the efficacy and safety of chidamide maintenance in adults with newly diagnosed double-expressor diffuse large B-cell lymphoma (DLBCL)…
- Trial name
- DEL-MRD-CHID (NCT07507318)
- Testing
- Chidamide
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Rong Tao
Chronic Myelogenous Leukemia
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
The main purpose of the study was to investigate whether nilotinib treatment can be safely suspended with no recurrence of CML in selected patients who responded optimally on this treatment
- Trial name
- ENESTfreedom (NCT01784068)
- Testing
- Nilotinib followed by treatment-free
- Where
- 113 sites in United States, Argentina and 17 more
- Volunteers
- 215 people
- Sponsor
- Novartis Pharmaceuticals
Stage II Colorectal Cancer
MRD Test in Common Risk Stage II Colorectal Cancer
Patients with colorectal cancer who were confirmed as stage II general risk type in the postoperative pathological report began to be enrolled.
- Trial name
- HuaMC-1 (NCT05795010)
- Testing
- MRD test
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
Various drugs have been added to different treatment regimens in order to improve the response rate in patients with Acute Lymphoblastic Leukemia, however, it has been shown that adding Bortezomib to the relapsing regimen…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease
- Trial name
- NCT05137860
- Testing
- Bortezomib
- Where
- Mexico
- Volunteers
- 56 people
- Sponsor
- Hospital General de Mexico
Multiple Myeloma (MM)
A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease
Multiple myeloma is a type of blood cancer that can come back even after effective treatment. After high-dose therapy and autologous stem cell transplantation (ASCT), some patients have no visible signs of disease, but small…
- Trial name
- TiTan (NCT07740486)
- Testing
- Teclistamab, Talquetamab, Daratumumab (Subcutaneously)
- Volunteers
- 248 people
- Sponsor
- Polish Myeloma Consortium
CD7+ T-ALL/LBL
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell…
- Trial name
- S101MRD (NCT07280494)
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia
Study of GDX012 in Patients With MRD Positive AML
The purpose of this first-in-human study is to assess the safety, tolerability, antileukemic activity and maximum tolerated dose (MTD) of GDX012 in AML patients who are MRD positive by multiparametric flow cytometry.
- Trial name
- NCT05001451
- Testing
- GDX012 Suspension for IV Infusion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- GammaDelta Therapeutics Limited
CRC (Colorectal Cancer)
A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy
The purpose of this study is to evaluate INCA33890 in the treatment of circulating tumor DNA-positive stage II/III microsatellite stable colorectal cancer after curative resection and chemotherapy.
- Trial name
- NEXERA-204 (NCT07823322)
- Testing
- INCA33890
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Leukemia
Pegasys in Patients With Chronic Myeloid Leukemia (CML)
The goal of this clinical research study is to learn if adding pegylated interferon-alfa 2a (Pegasys) to the TKI that you are already receiving can help to control CML.
- Trial name
- NCT01392170
- Testing
- PEG-IFNá-2a
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Leukemia, Acute Myeloid Leukemia
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further…
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma
- Trial name
- NCT03314974
- Testing
- HSCT with TBI Regimen, HSCT with Non-TBI Regimen
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
3-year Disease-free Survival
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
To evaluate 3-year disease-free survival after complete resection in patients with MRD-positive EGFR-sensitive mutations in Stage IA2-IB NSCLC treated with adjuvant befortinib and under routine observation (3y-DFS).
- Trial name
- NCT06561620
- Testing
- Befotertinib
- Where
- China
- Volunteers
- 592 people
- Sponsor
- Fudan University
NSCLC MRD ctDNA
Significance of MRD After Surgery in Driver Gene-positive and Driver Gene-negative Stage IB-IIA NSCLC
1. It has been controversial whether adjuvant therapy should be done for patients with stage IB NSCLC after surgery in clinical practice, and identifying patients with high-risk recurrence and those who can benefit from adjuvant…
- Trial name
- NCT05441566
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen People's Hospital
HPV Positive Oropharyngeal Squamous Cell Carcinoma
ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)
The purpose of this study is to test a new liquid biopsy assay for detecting residual disease after surgery in patients with HPV-associated head and neck cancer.
- Trial name
- Clear-HPVca (NCT06730412)
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Massachusetts Eye and Ear Infirmary